Tocilizumab (Actemra)

Tocilizumab (Actemra)

Tocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA). This article provides an overview...

Full description

Bibliographic Details
Main Authors:	Martin Sheppard, Faidra Laskou, Philip P. Stapleton, Shahryar Hadavi, Bhaskar Dasgupta
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2017-09-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	giant cell arteritis interleukin-6 monoclonal antibody rheumatoid arthritis tocilizumab vasculitis
Online Access:	http://dx.doi.org/10.1080/21645515.2017.1316909

Similar Items

EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
by: T. V. Beketova, et al.
Published: (2018-05-01)

Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis
by: Maxime Samson, et al.
Published: (2021-01-01)

Profile of tocilizumab and its potential in the treatment of giant cell arteritis
by: Mollan SP, et al.
Published: (2018-01-01)

Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
by: Sara Gale, et al.
Published: (2019-02-01)

New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)
by: Evgeniy L'vovich Nasonov, et al.
Published: (2010-05-01)

Letter to the editor
by: Francisco José Fernández - Fernández, et al.
Published: (2012-01-01)

Tocilizumab Vs Methotrexate in a Cohort of Patients Affected by Active GCA: A Comparative Clinical and Ultrasonographic Study
by: Grazzini S, et al.
Published: (2023-12-01)

INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
by: T. V. Beketova, et al.
Published: (2017-10-01)

Safety and Efficacy of Long-Term Tocilizumab in a Cohort of Patients with Giant Cell Arteritis: An Italian Monocentric Retrospective Study
by: Terribili R, et al.
Published: (2024-10-01)

Tocilizumab for relapsing and remitting giant cell arteritis: a case series
by: Pratyasha Saha, et al.
Published: (2022-10-01)

The Effect of Tocilizumab on Inflammatory Markers in Patients Hospitalized with Serious Infections. Case Series and Review of Literature
by: Mark Berman, et al.
Published: (2021-03-01)

Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature
by: Hiroki Wakabayashi, et al.
Published: (2019-04-01)

Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial
by: Arsene Mekinian, et al.
Published: (2020-09-01)

The efficacy of interleukin-6 inhibitor tocilizumab for takayasu’s arteritis, after insufficient response to previous treatment with glucocorticoids, methotrexate, cyclophosphamide, fludarabine. (A case report)
by: V. N. Antipova, et al.
Published: (2021-01-01)

The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis—study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study
by: Lena Kreis, et al.
Published: (2024-01-01)

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review
by: Ju-Yang Jung, et al.
Published: (2018-12-01)

INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
by: E. L. Nasonov, et al.
Published: (2018-01-01)

Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study
by: Akira Onishi, et al.
Published: (2025-03-01)

Secondary amyloidosis treated with tocilizumab as a complication of temporal arteritis
by: Maysoun Kudsi, et al.
Published: (2024-10-01)

Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6
by: Evgeny L. Nasonov, et al.
Published: (2024-09-01)

Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)
by: G. M. Koilubaeva, et al.
Published: (2022-05-01)

DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE
by: P. A. Shesternya, et al.
Published: (2019-09-01)

Perioperative Management of Takayasu Arteritis for Cardiac Surgery in a Patient Treated With Tocilizumab
by: Yoh Arita, MD, PhD, et al.
Published: (2020-12-01)

RAPID EFFECT OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS
by: E Yu Panasyuk, et al.
Published: (2011-08-01)

Tocilizumab prescribing criteria for COVID-19 patients
by: Ayman M. Al-Qaaneh, et al.
Published: (2021-04-01)

Safe and Efficient Use of Tocilizumab in Rheumatoid Arthritis Patient on Maintenance Hemodialysis: A Case Report
by: Paula Kilić, et al.
Published: (2023-08-01)

Utility and safety of tocilizumab in Takayasu arteritis with severe heart failure and muscle wasting
by: Toshiyuki Yano, et al.
Published: (2019-08-01)

Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
by: Pelechas E, et al.
Published: (2019-09-01)

Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis
by: Han Joo Baek, et al.
Published: (2019-07-01)

Comparison of different treatment modalities of tocilizumab in children with systemic juvenile idiopathic arthritis
by: M. M. Kostik, et al.
Published: (2013-09-01)

Tocilizumab: Another medication related to osteonecrosis of the jaws? A case report and literature review
by: Sakkas, Andreas, et al.
Published: (2021-04-01)

Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
by: Michaela Butryn, et al.
Published: (2021-06-01)

SEVERE HYPOFIBRINOGENEMIA IN A PATIENT WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB: CASE-BASED REVIEW
by: Željka Kardum, et al.
Published: (2023-12-01)

Primary pathologic role of interleukin-6 in rheumatoid arthritis
by: G.L. Bajocchi, et al.
Published: (2013-05-01)

Safety of Therapy with Tocilizumab and Other Interleukin Inhibitors
by: V. I. Petrov, et al.
Published: (2022-04-01)

A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis
by: Shuntaro Saito, et al.
Published: (2017-10-01)

European Headache Federation recommendations for neurologists managing giant cell arteritis
by: S. P. Mollan, et al.
Published: (2020-03-01)

Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study
by: Christophe Schmitt, et al.
Published: (2022-06-01)

Clinical efficacy and safety of tocilizumab in the treatment of seropositive rheumatoid arthritis patients in India
by: Abhishek Kumar, et al.
Published: (2020-01-01)

LONG-TERM SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS OF MODERATE OR HIGH ACTIVITY (RESULTS OF PHASE III MULTICENTER EXTENSION CLINICAL STUDY ML28124)
by: E. L. Nasonov, et al.
Published: (2018-07-01)